U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 21 - 22 of 22 results

RANITIDINE BISMUTH CITRATE

MORE DETAILS

  7AJ51I17KG

Status:
US Approved Rx (2007)
Source:
ANDA077405
(2007)
Source URL:
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077405
First approved in 1983
Source:
ZANTAC 150 by GLAXO GRP LTD
Source URL:
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018703
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Histamine H2 receptor
46
Histamine H2 receptor
46
Histamine H2 receptor
46
Conditions:
Zollinger-Ellison syndrome
17
Duodenal ulcer
42
Gastroesophageal reflux disease
59
Gastric ulcer
67
Ranitidine, a histamine H2-receptor antagonist, is now well established as a potent inhibitor of gastric acid secretion effective in the treatment and prophylaxis of gastrointestinal lesions aggravated by gastric acid secretion.

RANITIDINE HYDROCHLORIDE

MORE DETAILS

  BK76465IHM

Status:
US Approved Rx (2007)
Source:
ANDA077405
(2007)
Source URL:
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077405
First approved in 1983
Source:
ZANTAC 150 by GLAXO GRP LTD
Source URL:
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018703
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Histamine H2 receptor
46
Histamine H2 receptor
46
Histamine H2 receptor
46
Conditions:
Zollinger-Ellison syndrome
17
Duodenal ulcer
42
Gastroesophageal reflux disease
59
Gastric ulcer
67
Ranitidine, a histamine H2-receptor antagonist, is now well established as a potent inhibitor of gastric acid secretion effective in the treatment and prophylaxis of gastrointestinal lesions aggravated by gastric acid secretion.
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966